![]()
|
Report Date : |
17.03.2008 |
IDENTIFICATION
DETAILS
|
Name : |
MEDICRAFT PHARMACEUTICALS (PVT.) LIMITED |
|
|
|
|
Registered Office : |
Plot # 126-B, Industrial Estate, Jamrud Road, Peshawar |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
1991 |
|
|
|
|
Com. Reg. No.: |
0024422 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture and Marketing of Pharmaceutical Products |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
MEDICRAFT PHARMACEUTICALS (PVT.) LIMITED
|
Registered Address & Factory |
|
Plot # 126-B, Industrial Estate, Jamrud Road, Peshawar, Pakistan |
|
Tel |
92 (91) 5816000 |
|
Fax |
92 (91) 5891238 |
|
Nature of Business |
Manufacture & Marketing of Pharmaceutical Products |
|
Year Established |
1991 |
|
Registration # |
0024422 |
In Peshawar at present
M/s Dilroze Khan & Co.
(Chartered Accountants)
Subject Company was established as a Private Limited Company in 1991
|
Authorized Capital |
Rs. 30,000,000/- divided into 300,000 shares of Rs. 100/- each |
|
Issued & Paid up Capital |
Rs 11,310,000/- divided into 113,100 shares of Rs. 100/- each |
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Ishtiaq Ahmed Mr. Aftab Ahmed Mr. Ashfaq Ahmed Mr. Imtiaz Ahmed |
Pakistani Pakistani Pakistani Pakistani |
Plot # 126-B, Industrial Estate, Jamrud Road, Peshawar Plot # 126-B, Industrial Estate, Jamrud Road, Peshawar Plot # 126-B, Industrial Estate, Jamrud Road, Peshawar Plot # 126-B, Industrial Estate, Jamrud Road, Peshawar |
Business Business Business Business |
Chief Executive Director Director Director |
Names
Mr. Ishtiaq Ahmed
Mr. Aftab Ahmed
Mr. Ashfaq Ahmed
Mr. Imtiaz Ahmed
A. Subsidiary
None
B. Associated Companies
- Do -
Manufacture & Marketing of Pharmaceutical Products by its brand name including ALLERGON, AMCHLO, AMNORIL, ANHIBIT, ASTHACURE, BACTIMED, BACTIRID, BIOMED, BONEMED, CARDIOWEL, CEFOMED, CEFPOMED, CHLOROMED, CIPROKING, CIPROMED, CLIK, CT-COLIN, CTZINE, DEPCURE, DICLOKING, DYRID-P, ENZOVIT, EPIGRAL, FCOZOLE, FOLVIT, GYNEMED, IROMED, KEFZOMED, KUFRID, LEVOMED, LINKOWIN, LIPOMED, LOROKING, MALACURE, MALSIM, MEDFEN, MEDGEL, MEDGLOBIN, MEDIKUF, MEDIMOX, MEDIPLEX - L, MEDIRON, METFORMED, METRONIDAZOLE, MOTIL, NEUROZIN, NOXACIN,
OFLOMED, OFLOWIN, OMED, OZAPINE, PAINRID, PARADEXAMOL,
PARAMED, PAYARAM, PEPCIMED, PERIACTONE, PHENOMED, PMALAMED, POSTAGLIN, RANMIC, RELAXAMED, RESPIDONE, RIDBAC, SIGMA, TBRID, TIZMED, TREMOMED, ULCERID, ULTOMED, UNIVIT, UNIVIT-M, VEENA FORTE, VELOMED, VENTOMED
82
|
Year |
In Pak Rupees |
|
2006 |
70,000,000/- (Estimated) |
Subject represent some companies regarding pharmaceutical raw material belongs to India, China & Europe
Mainly Individuals, Retailers, Pharmacies, Hospitals located in Peshawar & Quetta.
Habib Bank Limited, Super Market Branch, Peshawar Cantt, Pakistan.
(Mortgage obtained PKR 63,000,000/-)
Bank Alfalah Limited, Islamia Road, Peshawar Cantt, Pakistan.
(Mortgage obtained PKR 97,140,000/-)
Sarhad Chamber of Commerce & Industry.(SCCI)
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 62.90 |
|
UK Pound |
1 |
Rs.126.75 |
|
Euro |
1 |
Rs. 98.35 |
Subject Company was established in 1991 and is engaged in manufacture & marketing of Pharmaceutical Products. Trade relations are reported as fair. Subject Company can be considered for normal business dealings at usual trade terms and conditions.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)